AstraZeneca's venture capital arm, MedImmune Ventures, focuses on equity investments in private companies within biopharmaceuticals, medical, and healthcare technology. Additionally, its BioVentureHub utilizes an open innovation model to advance new drugs and medical devices, with a strategic emphasis on oncology, cardiovascular, renal & metabolism (CVRM), and respiratory & immunology (R&I).
100% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is seed (50% of deals). Average disclosed round size is $55.4M (across 3 rounds with reported amounts).
Portfolio
4
Fund Size
$400M
Top Stage
Seed
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Syneron Bio | Series B | $150M | Mar 2026 |
| Syneron Bio | Series A | — | Dec 2025 |
| CCassidy Bio | Seed | $8M | Nov 2025 |
 Promise Bio | Seed | $8.3M | Dec 2024 |
Top Co-Investors
GL Ventures2 shared
5Y Capital2 shared
Sinovation2 shared
Awz Ventures1 shared
Pfizer Ventures1 shared
Ahren Innovation Capital1 shared
10D VC1 shared
GREE1 shared
Decheng1 shared
Abu Dhabi Investment Authority1 shared
BioTrack Capital1 shared
LAV1 shared
Last updated: 10 April 2026